SPNGNX_logo_hrz.jpg
Spinogenix Granted FDA Orphan Drug Designation for SPG302 for the Treatment of Amyotrophic Lateral Sclerosis
June 07, 2021 07:00 ET | Spinogenix, Inc.
SAN DIEGO, June 07, 2021 (GLOBE NEWSWIRE) -- Spinogenix, Inc. a pharmaceutical company focused on the development of novel synaptogenic small molecule therapies for central nervous system disorders...
WAVE LOGO NEW COLOR SWOOSH.jpg
Wave Life Sciences Reports First Quarter 2021 Financial Results and Provides Business Update
May 13, 2021 07:30 ET | Wave Life Sciences USA, Inc.
Clinical trials underway with next-generation candidates incorporating PN chemistry Clinical data from PN chemistry programs expected in 2022 In vivo ADAR editing data for AATD program on track for...
retro.jpg
Retrotope Announces Completion of Enrollment in Phase 2 Study of RT001 in Patients with Amyotrophic Lateral Sclerosis (ALS)
April 21, 2021 07:00 ET | Retrotope
LOS ALTOS, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases,...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Announces First Patient Treated in Phase IB AL Amyloidosis Trial with STI-6129, an Anti-CD38 Antibody-Drug Conjugate
March 18, 2021 09:00 ET | Sorrento Therapeutics, Inc.
STI-6129 is an antibody-drug conjugate (ADC) composed of a fully human monoclonal anti-CD38 antibody covalently bound by a proprietary chemical linker to a duostatin tubulin inhibitor.Amyloid Light...
retro.jpg
Retrotope Announces Initiation of Phase 2 Study of RT001 in Patients with Amyotrophic Lateral Sclerosis (ALS)
March 17, 2021 07:00 ET | Retrotope
LOS ALTOS, Calif., March 17, 2021 (GLOBE NEWSWIRE) -- Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases,...
retro.jpg
Retrotope to Present at H.C. Wainwright Global Life Sciences Conference
March 03, 2021 16:05 ET | Retrotope
LOS ALTOS, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases,...
retro.jpg
Retrotope Granted Rare Pediatric Disease Designation from FDA for Lead Development Candidate, RT001, in Two Life-Threatening Neurodegenerative Indications
February 25, 2021 07:00 ET | Retrotope
Company Currently Conducting Late-Stage Clinical Trials in Both Infantile Neuroaxonal Dystrophy (INAD) and Friedreich’s Ataxia (FA) RT001 also Granted Fast Track Designation by FDA in FA; Orphan Drug...
WAVE LOGO NEW COLOR SWOOSH.jpg
Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2020 Financial Results on March 4, 2021
February 23, 2021 08:00 ET | Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
retro.jpg
Retrotope Appoints Rick E Winningham as Chairman of Board of Directors in Advance of Key Clinical Trial Data Readouts
February 11, 2021 07:00 ET | Retrotope
LOS ALTOS, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases,...
WAVE LOGO NEW COLOR SWOOSH.jpg
Wave Life Sciences Highlights Pipeline Progress and Expansion Leveraging New PN Backbone Chemistry Modifications
January 11, 2021 08:00 ET | Wave Life Sciences USA, Inc.
Three clinical trials to begin in 2021 with compounds containing Wave’s novel PN backbone chemistry modifications Data from ongoing PRECISION-HD and OLE clinical trials for Huntington’s disease...